A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Sesderma LACTYFERRIN™ Forte and Sesderma ZINC Defense™ (Liposomal Bovine Lactoferrin (LbLf) and Liposomal Zn (LZn)) and Standard of Care (SOC) vs SOC in the Treatment of Non-hospitalized Patients With COVID-19

Avella et al., NCT05783180, NCT05783180, Nov 2024
Estimated 40 patient lactoferrin early treatment RCT with results not reported over 1 year after estimated completion.
Important missing comments or errors? Let us know.
Study covers lactoferrin and zinc.
Avella et al., 1 Nov 2024, Double Blind Randomized Controlled Trial, placebo-controlled, USA, trial NCT05783180 (history). Contact: maria.bertoli@keraltyhospital.com, gmasferrer@keraltyhospital.com.
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0